Comparison of effects of epidermal and insulin-like growth factors, gastrin releasing peptide and retinoic acid on fetal lung cell growth and maturation in vitro.
The role in cell multiplication and maturation of several factors present in the late fetal lung was explored on isolated fetal rat pulmonary fibroblasts and alveolar epithelial type II cells cultivated in serum-free medium. The low degree of reciprocal contamination of each cell population was assessed by immunocytochemistry. Epidermal Growth Factor (EGF) stimulated thymidine incorporation and DNA accumulation in both cell types. In type II cells, it increased labeled-choline incorporation into surfactant phosphatidylcholine (PC), consistently with previous data obtained with lung explant cultures, but not into non-surfactant PC. Insulin-like growth factor (IGF)-I slightly stimulated DNA accumulation in fibroblasts although it did not significantly stimulate thymidine incorporation, contrary to IGF-II which presented a dose-dependent stimulating activity of thymidine incorporation. Neither IGF-I nor IGF-II stimulated type II cell growth. IGFs thus appear to primarily control the growth of lung mesenchyme. In type II cells, they stimulated the most non-surfactant PC biosynthesis. Gastrin releasing peptide (GRP) which was recently reported to promote fetal lung growth in vivo and to stimulate surfactant biosynthesis in lung organ culture revealed as a growth factor for type II cells only, at concentrations below 10(-9) M. At concentration 10(-8) M, although it did not affect DNA synthesis, GRP tended to increase surfactant and non-surfactant-PC biosynthesis. Retinoic acid inhibited thymidine incorporation into type II cells on a dose-dependent manner but nevertheless enhanced surfactant-PC biosynthesis to a similar extent as EGF. It is suggested that retinoic acid may represent a differentiation or maturation factor for the alveolar epithelium.
Centre de Biologie Cellulaire, Centre National de la Recherche Scientifique, Ivry sur Seine, France.
C
C
Fraslon
J R
JR
Bourbon
D000818:Animals; D002455:Cell Division; D002794:Choline / Q000378:metabolism; D004247:DNA / Q000378:metabolism; D004815:Epidermal Growth Factor / Q000494:pharmacology*; D004848:Epithelium / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D005260:Female; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D005455:Fluorescent Antibody Technique; D019886:Gastrin-Releasing Peptide; D007633:Keratins / Q000378:metabolism; D008168:Lung / Q000187:drug effects* / Q000196:embryology / Q000378:metabolism / Q000648:ultrastructure; D008854:Microscopy, Electron; D010455:Peptides / Q000494:pharmacology*; D010713:Phosphatidylcholines / Q000096:biosynthesis / Q000378:metabolism; D011247:Pregnancy; D011650:Pulmonary Alveoli / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D011663:Pulmonary Surfactants / Q000096:biosynthesis / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D013002:Somatomedins / Q000494:pharmacology*; D013936:Thymidine / Q000378:metabolism; D014212:Tretinoin / Q000494:pharmacology*; D014746:Vimentin / Q000378:metabolism
D010455:Peptides; D010713:Phosphatidylcholines; D011663:Pulmonary Surfactants; D013002:Somatomedins; D014746:Vimentin; D014212:Tretinoin; D004815:Epidermal Growth Factor; D007633:Keratins; D019886:Gastrin-Releasing Peptide; D004247:DNA; D002794:Choline; D013936:Thymidine